These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 6197164)
1. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues. Camiolo SM; Markus G; Englander LS; Siuta MR; Hobika GH; Kohga S Cancer Res; 1984 Jan; 44(1):311-8. PubMed ID: 6197164 [TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors. Markus G; Camiolo SM; Kohga S; Madeja JM; Mittelman A Cancer Res; 1983 Nov; 43(11):5517-25. PubMed ID: 6193874 [TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators in human malignant melanoma. Markus G; Kohga S; Camiolo SM; Madeja JM; Ambrus JL; Karakousis C J Natl Cancer Inst; 1984 Jun; 72(6):1213-22. PubMed ID: 6374238 [TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma. Festuccia C; Vincentini C; di Pasquale AB; Aceto G; Zazzeroni F; Miano L; Bologna M Oncol Res; 1995; 7(3-4):131-8. PubMed ID: 8555646 [TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays. Camiolo SM; Greco WR Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257 [TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator content of neoplastic and benign human prostate tissues; fibrin augmentation of an activator activity. Camiolo SM; Markus G; Evers JL; Hobika GH; DePasquale JL; Beckley S; Grimaldi JP Int J Cancer; 1981 Feb; 27(2):191-8. PubMed ID: 6169657 [TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Kirchheimer JC; Pflüger H; Ritschl P; Hienert G; Binder BR Invasion Metastasis; 1985; 5(6):344-55. PubMed ID: 4066206 [TBL] [Abstract][Full Text] [Related]
8. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells. Waghray A; Webber MM Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041 [TBL] [Abstract][Full Text] [Related]
9. [Tissue plasminogen activator activity in early prostatic cancer and in bone metastases of prostatic cancer]. Pflüger H; Kirchheimer J; Ritschl P; Köller A; Hienert G; Binder BR Wien Klin Wochenschr; 1984 Sep; 96(17):658-61. PubMed ID: 6083673 [TBL] [Abstract][Full Text] [Related]
10. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma. Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195 [TBL] [Abstract][Full Text] [Related]
11. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate. Wilson MJ; Ludowese C; Sinha AA; Estensen RD Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400 [TBL] [Abstract][Full Text] [Related]
12. Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase. Holmberg L; Kristoffersson AC; Lecander I; Wallén P; Astedt B Scand J Clin Lab Invest; 1982 Jun; 42(4):347-54. PubMed ID: 6753100 [TBL] [Abstract][Full Text] [Related]
13. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Kohga S; Harvey SR; Weaver RM; Markus G Cancer Res; 1985 Apr; 45(4):1787-96. PubMed ID: 3884145 [TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior. Wilson MJ; Sinha AA Cell Mol Biol Res; 1993; 39(8):751-60. PubMed ID: 7951414 [TBL] [Abstract][Full Text] [Related]
15. Immunological characterization of plasminogen activator activities in human tissues and body fluids. Rijken DC; Wijngaards G; Welbergen J J Lab Clin Med; 1981 Apr; 97(4):477-86. PubMed ID: 6782183 [TBL] [Abstract][Full Text] [Related]
16. Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Wilson EL; Becker ML; Hoal EG; Dowdle EB Cancer Res; 1980 Mar; 40(3):933-8. PubMed ID: 7193517 [TBL] [Abstract][Full Text] [Related]
17. Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue. Shih SJ; Dall'Era MA; Westphal JR; Yang J; Sweep CG; Gandour-Edwards R; Evans CP Prostate Cancer Prostatic Dis; 2003; 6(2):131-7. PubMed ID: 12806371 [TBL] [Abstract][Full Text] [Related]
18. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer. Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433 [TBL] [Abstract][Full Text] [Related]
19. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. McGowen R; Biliran H; Sager R; Sheng S Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Cozzi PJ; Wang J; Delprado W; Madigan MC; Fairy S; Russell PJ; Li Y Hum Pathol; 2006 Nov; 37(11):1442-51. PubMed ID: 16949925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]